Successful patient outcomes demonstrated with edwards' sapien m3 and evoque systems, new data presented at tct 2025

San francisco--(business wire)--edwards lifesciences (nyse: ew) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. one-year data from the encircle single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in the lancet. thirty-day data from the evoque system sts/acc tvt registry, the largest real-world transcatheter tricuspid valve replacement.
EW Ratings Summary
EW Quant Ranking